Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 1133-1134 |
| Number of pages | 2 |
| Journal | The Lancet |
| Volume | 386 |
| Issue number | 9999 |
| DOIs | |
| Publication status | Published - 19 Sep 2015 |
Fingerprint
Cite this
}
Oseltamivir for influenza. / Jones, Mark; Hama, Rokuro; Del Mar, Chris.
In: The Lancet, Vol. 386, No. 9999, 19.09.2015, p. 1133-1134.Research output: Contribution to journal › Letter › Research › peer-review
TY - JOUR
T1 - Oseltamivir for influenza
AU - Jones, Mark
AU - Hama, Rokuro
AU - Del Mar, Chris
PY - 2015/9/19
Y1 - 2015/9/19
N2 - [Extract] In their Article (May 2, p 1729) on oseltamivir treatment for influenza, Joanna Dobson and colleagues reported both fewer admittances to hospital for those treated with oseltamivir in the subgroup of patients classified as infected and fewer lower respiratory tract complications in patients treated with antibiotics as a surrogate for severity than in placebo recipients. However, our Cochrane review found insufficient evidence of a difference between groups for complications classified as serious or leading to patient withdrawal, or for rate of admittance to hospital.
AB - [Extract] In their Article (May 2, p 1729) on oseltamivir treatment for influenza, Joanna Dobson and colleagues reported both fewer admittances to hospital for those treated with oseltamivir in the subgroup of patients classified as infected and fewer lower respiratory tract complications in patients treated with antibiotics as a surrogate for severity than in placebo recipients. However, our Cochrane review found insufficient evidence of a difference between groups for complications classified as serious or leading to patient withdrawal, or for rate of admittance to hospital.
UR - http://www.scopus.com/inward/record.url?scp=84942154585&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(15)00200-7
DO - 10.1016/S0140-6736(15)00200-7
M3 - Letter
VL - 386
SP - 1133
EP - 1134
JO - Lancet
JF - Lancet
SN - 0140-6736
IS - 9999
ER -